Technology Bundle ID: TAB-1827

A Novel Treatment for Malarial Infections

Request More Info
Licensing Contact:
Primary Inventors: 
Sanjay Desai (NIAID)
Development Stage: 
Pre-Clinical (in vitro)
Development Status: 
  • In vitro data available
  • In vivo data available (animal)
Institute or Center: 
NIAID

The inventions described herein are antimalarial small molecule inhibitors of the plasmodial surface anion channel (PSAC), an essential nutrient acquisition ion channel expressed on human erythrocytes infected with malaria parasites. These inhibitors were discovered by high-throughput screening of chemical libraries and analysis of their ability to kill malaria parasites in culture. Two separate classes of inhibitors were found to work synergistically in combination against PSAC and killed malaria cultures at markedly lower concentrations than separately. These inhibitors have high affinity and specificity for PSAC and have acceptable cytotoxicity profiles. Preliminary in vivo testing of these compounds in a mouse malaria model is currently ongoing.

Applications:
  • Treatment of malarial infections
Advantages:
  • Novel drug treatment for malarial infections
  • Synergistic effect of these compounds on PSAC

Patents

PCT Application PCT/US09/50637
Filed on 2009-07-15
US Application 17/140,704
Filed on 2021-01-04
US Application 61/083,000
Filed on 2008-07-23
US Pat 10,881,669

Issued 2021-01-05
US Pat 8,618,090

Issued 2013-12-31
US Pat 9,394,316

Issued 2016-07-19
US Pat 9,974,796

Issued 2018-05-22

Publications

Desai SA, et al.
PMID 10984055
Kang M, et al.
PMID 15843600

Updated

Sep 1, 2008

Data Source: 
tts